OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer Survivors

May 8th 2021

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

May 8th 2021

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

Dr. Powell on the Risk of ILD with Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 8th 2021

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

May 7th 2021

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL

May 6th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Dr. Yacoub on Efficacy and Safety Results With Parsaclisib in Myelofibrosis

May 6th 2021

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Dr. Goy on the Durability of Response With Brexucabtagene Autoleucel in MCL

May 6th 2021

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Marshall on Early Data With Trastuzumab Deruxtecan in HER2+ CRC

May 6th 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

Dr. Grothey on the Potential Role of ctDNA in Screening for CRC

May 5th 2021

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

May 5th 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Dr. Alkharabsheh on Future Research Directions in MPNs

May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

May 4th 2021

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in Osteosarcomas

May 4th 2021

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Dr. Rapisuwon on the Potential Utility of Toripalimab in Melanoma Subtypes

May 4th 2021

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCL

May 4th 2021

Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Verstovsek on the Efficacy of Ruxolitinib Plus CPI-0610 in Myelofibrosis

May 3rd 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Dr. Barrientos on Selecting Between BCL-2 Inhibitors and BTK Inhibitors in CLL

May 3rd 2021

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple Myeloma

May 3rd 2021

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast Cancer

May 3rd 2021

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.